Production (Stage)
Innate Pharma S.A.
IPHA
$2.08
-$0.09-4.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -53.52M | -45.35M | -36.82M | -22.56M | -8.20M |
| Total Depreciation and Amortization | 2.16M | 2.48M | 2.80M | 4.17M | 5.50M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.54M | 979.30K | 401.50K | 1.30M | 2.17M |
| Change in Net Operating Assets | 42.35M | 28.36M | 14.07M | -10.33M | -34.70M |
| Cash from Operations | -7.47M | -13.53M | -19.55M | -27.43M | -35.22M |
| Capital Expenditure | -422.90K | -387.90K | -351.40K | -367.30K | -379.40K |
| Sale of Property, Plant, and Equipment | -- | 80.70K | 162.30K | 162.30K | 162.30K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 10.38M | 17.10M | 23.79M | 23.18M | 22.55M |
| Cash from Investing | 9.96M | 16.79M | 23.61M | 22.97M | 22.33M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.94M | -7.06M | -5.19M | -3.77M | -2.36M |
| Issuance of Common Stock | 2.93M | 1.53M | 140.00K | 267.50K | 395.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -6.50M | -5.99M | -5.46M | -3.81M | -2.13M |
| Foreign Exchange rate Adjustments | -546.30K | -344.70K | -138.20K | 79.00K | 296.30K |
| Miscellaneous Cash Flow Adjustments | -100.00 | 400.00 | 1.00K | 1.00K | 1.00K |
| Net Change in Cash | -4.56M | -3.08M | -1.54M | -8.18M | -14.72M |